Robeco Institutional Asset Management B.V. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 12.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 402,958 shares of the biopharmaceutical company’s stock after selling 57,644 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.39% of Regeneron Pharmaceuticals worth $305,551,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in REGN. Capital Management Associates Inc bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $212,000. LCM Capital Management Inc lifted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after purchasing an additional 13 shares during the last quarter. Tred Avon Family Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 24.7% in the third quarter. Tred Avon Family Wealth LLC now owns 662 shares of the biopharmaceutical company’s stock worth $502,000 after purchasing an additional 131 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Regeneron Pharmaceuticals by 6.4% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,171 shares of the biopharmaceutical company’s stock worth $11,504,000 after purchasing an additional 911 shares in the last quarter. Finally, Drum Hill Capital LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth $227,000. Institutional investors own 83.31% of the company’s stock.
Insider Activity at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 in the last quarter. Company insiders own 6.97% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Raymond James Financial boosted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Truist Financial increased their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $845.59.
Get Our Latest Analysis on REGN
Regeneron Pharmaceuticals Stock Up 3.3%
Shares of REGN stock opened at $807.48 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.75 and a 12 month high of $859.34. The firm has a market cap of $83.14 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The stock has a 50 day moving average of $791.41 and a 200-day moving average of $721.87. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the business earned $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.98 EPS for the current year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
